These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 16728631)

  • 1. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
    Shaked Y; Kerbel RS
    Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis as a therapeutic target.
    Ferrara N; Kerbel RS
    Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
    Gasparini G; Longo R; Fanelli M; Teicher BA
    J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic scheduling of lower dose cancer chemotherapy.
    Gately S; Kerbel R
    Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of angiogenesis in cancer patients.
    Verheul HM; Pinedo HM
    Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic drugs in ovarian cancer.
    Markman M
    Expert Opin Pharmacother; 2009 Oct; 10(14):2269-77. PubMed ID: 19671017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.